Author:
Wu Huan,Sun Chenggong,Cao Wenyu,Teng Qiuli,Ma Xinyue,Schiöth Helgi B.,Dong Ruifen,Zhang Qing,Kong Beihua
Reference46 articles.
1. Cancer statistics, 2022;Siegel;CA A Cancer J. Clin.,2022
2. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer;Moore;N. Engl. J. Med.,2018
3. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer;Ray-Coquard;N. Engl. J. Med.,2019
4. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial;Li;JAMA Oncol.,2023
5. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial;Pujade-Lauraine;Lancet Oncol.,2017